204 related articles for article (PubMed ID: 38707996)
1. Secondary Hyperparathyroidism and Cognitive Decline.
Crepeau P; Fedorova T; Morris-Wiseman LF; Mathur A
Curr Transplant Rep; 2023 Jun; 10(2):60-68. PubMed ID: 38707996
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
3. Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia.
Mathur A; Ahn JB; Sutton W; Chu NM; Gross AL; Segev DL; McAdams-DeMarco M
Nephrol Dial Transplant; 2022 Oct; 37(11):2111-2118. PubMed ID: 35512551
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative Parathyroid Hormone Monitoring-Guided Subtotal Parathyroidectomy is an Effective and Valid Surgical Procedure for Secondary Hyperparathyroidism.
Guzel G; Unal DS; Ozen A; Aydemir M; Calis H; Boz A; Arici C
Sisli Etfal Hastan Tip Bul; 2023; 57(2):272-278. PubMed ID: 37899807
[TBL] [Abstract][Full Text] [Related]
5. Management of secondary hyperparathyroidism: how and why?
Komaba H; Kakuta T; Fukagawa M
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):37-45. PubMed ID: 28044233
[TBL] [Abstract][Full Text] [Related]
6. The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS.
Cannata-Andía JB; Carrera F
NDT Plus; 2008 Jan; 1(Suppl 1):i2-i6. PubMed ID: 25983952
[TBL] [Abstract][Full Text] [Related]
7. The Eucalcemic Patient With Elevated Parathyroid Hormone Levels.
Shaker JL; Wermers RA
J Endocr Soc; 2023 Feb; 7(4):bvad013. PubMed ID: 36793479
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Secondary Hyperparathyroidism and Posttransplant Tertiary Hyperparathyroidism.
Egan CE; Qazi M; Lee J; Lee-Saxton YJ; Greenberg JA; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
J Surg Res; 2023 Nov; 291():330-335. PubMed ID: 37506432
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
10. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation.
Platt A; Wilson J; Hall R; Ephraim PL; Morton S; Shafi T; Weiner DE; Boulware LE; Pendergast J; Scialla JJ;
Am J Kidney Dis; 2024 Jan; 83(1):58-70. PubMed ID: 37690631
[TBL] [Abstract][Full Text] [Related]
12. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
[TBL] [Abstract][Full Text] [Related]
13. Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.
Oltmann SC; Madkhali TM; Sippel RS; Chen H; Schneider DF
J Surg Res; 2015 Nov; 199(1):115-20. PubMed ID: 25982045
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidism.
Martins P; Schmitt F; Almeida H; Frazão JM
Nephrol Dial Transplant; 2008 Sep; 23(9):2889-94. PubMed ID: 18398016
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study.
Rottembourg J; Ureña-Torres P; Toledano D; Gueutin V; Hamani A; Coldefy O; Hebibi H; Guincestre T; Emery C
Clin Kidney J; 2019 Dec; 12(6):871-879. PubMed ID: 31807302
[TBL] [Abstract][Full Text] [Related]
16. [MiR-301a-5p modulates parathyroid hormone secretion in secondary hyperparathyroidism possibly by regulating calcium-sensing receptor].
Liu L; Qian L; Li P; Li J; Huang S; Yi W; Liu S; Wu W
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Aug; 43(8):1363-1370. PubMed ID: 37712273
[TBL] [Abstract][Full Text] [Related]
17. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
18. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.
Bozic M; Diaz-Tocados JM; Bermudez-Lopez M; Forné C; Martinez C; Fernandez E; Valdivielso JM
Nephrol Dial Transplant; 2022 Mar; 37(4):663-672. PubMed ID: 34021359
[TBL] [Abstract][Full Text] [Related]
19. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
20. Low Parathyroid Hormone
Guo W; Zhang H; Zhang Y; Huang H; Liu W; Diao Z
Front Endocrinol (Lausanne); 2022; 13():869330. PubMed ID: 35634511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
